A phase 1 trial including HER-2 positive breast cancer patients that progressed under trastuzumab-based therapy was recently conducted (NCT03281824) and preliminary data reveals a favorable tolerability profile and indicates that there will probably be a phase 2 study [110]. This evidence concerns the gene ERBB2 and breast carcinoma.